Taxane‑based chemotherapy was associated with more favorable outcomes than pemetrexed in dramatic progression after osimertinib resistance, with higher non‑hematologic toxicity. These findings, supported by exploratory in vitro sensitivity, warrant prospective validation.

In elderly PCNSL patients, R-MPV without routine WBRT provides effective disease control while being associated with less structural brain change. CSF IL-10 may represent a potential biomarker of susceptibility to treatment-related brain structural alterations.

Patients received either pemetrexed plus cisplatin (control group, n=56) or the same regimen with osimertinib (experimental group, n=56). The incidence of adverse reactions did not differ significantly between groups (P>0.05). In this retrospective cohort, the addition of osimertinib to platinum-based chemotherapy was associated with improved disease control and prolonged survival, along with greater reductions in angiogenesis-related and tumor marker levels, without increasing treatment-related toxicity.

He received afatinib as frontline treatment and showed a partial response; however, the right lung lesion progressed after 14 months of treatment...Because EGFR testing using resected tissue showed only the original mutation, we switched his regimen to pemetrexed and carboplatin...Although an association between MET amplification and rapidly progressive lung cancer has been predicted previously, to the best of our knowledge, this is the first report on the potential contribution of other mutations, such as those in RNA-binding motif 10, during MET-driven rapid progression. Our report highlights the importance of more active utilization of molecular profiling for the emergence of resistance during tyrosine kinase inhibitor use and the early identification of MET amplification and timely initiation of MET-targeted therapy, such as MET inhibitors in combination with EGFR-TKIs, to potentially mitigate rapid disease progression and clinical deterioration.

However, epcoritamab induced a rapid systemic response along with partial neurological improvement. This case highlights the potential role of bispecific antibody therapy in refractory DLBCL with CNS involvement, an area of significant unmet clinical need.

P4, N=108, Recruiting, Chinese University of Hong Kong

Based on the above results, the patient received chemotherapy with carboplatin and pemetrexed disodium combined with targeted therapy using the EGFR tyrosine kinase inhibitor (TKI) almonertinib mesylate tablets. The two cases reported in this paper demonstrate that targeted and immune treatment plans based on the tissue of origin of the tumor can serve as a clinical option for patients with CUP. These findings may provide new information and references for clinical decision-making in the management of CUP.

P3, N=200, Recruiting, Children's Cancer Group, China | Trial primary completion date: Dec 2025 --> Dec 2026

P2, N=16, Recruiting, Wake Forest University Health Sciences | Trial completion date: Jan 2027 --> Jul 2027

He received five cycles of first-line chemotherapy with pemetrexed and cisplatin (PP regimen), which was followed by sequential maintenance therapy with nivolumab (200 mg, Q3W). For patients with PD-L1-high advanced NSCLC, nivolumab monotherapy can induce deep and durable immune responses, enabling long-term survival with a manageable safety profile, even in elderly patients with multiple comorbidities. This case provides compelling real-world evidence for the remarkable efficacy of immune checkpoint inhibitors.

Overall survival data were immature (data maturity, 4%). The ACROSS2 trial provides the first prospective evidence supporting a genotype-directed, chemotherapy-targeted intensification approach favoring aumolertinib plus carboplatin-pemetrexed for this molecularly defined population.

In non-squamous (NSQ) NSCLC with PD-L1 ≥1%, pemetrexed-platinum plus single immunotherapy (SI), with maintenance pemetrexed plus anti-PD-(L)1, may be the most appropriate option...With increasing PD-L1 expression, chemo-immunotherapy [CT plus a single anti-PD-(L)1 antibody] was associated with durable clinical benefit. However, additional evidence is needed to compare continuous DI with other MT-containing strategies, particularly for progression-free survival in key subgroups.